Direct methods for assessing adherence to antihypertensive therapy: witnessed intake and therapeutic drug monitoring

Low adherence to therapy is one of the main causes of pseudo-resistant arterial hypertension (AH), associated with an increased risk of cardiovascular complications and higher direct and indirect medical costs. Adherence assessment is a crucial step in the management of patients with uncontrolled AH, particularly when therapeutic resistance is suspected. There is no "gold standard" for assessing therapy adherence. Therefore, beyond indirect methods (though simple, they are relatively unreliable), direct approaches are increasingly being utilized. These include witnessed medication intake by medical personnel — conducted alongside repeated ambulatory blood pressure monitoring using portable devices or repeated measurements by a specialist — and therapeutic drug monitoring of medications or their metabolites in biological fluids using ultra-high-performance liquid chromatography-tandem mass spectrometry. This narrative review summarizes key findings from studies on the application of these methods, outlines their respective advantages and limitations, and provides practical recommendations for their integration into everyday clinical practice. Early and simultaneous implementation of these strategies can help avoid unnecessary complex and costly diagnostic procedures in some cases and allows for more accurate identification of truly resistant AH – a patient group of scientific and clinical relevance. The use of these approaches improves the cost-effectiveness of treatment, helps uncover non-medical barriers to adherence, and strengthens the physician–patient relationship.

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80. DOI:10.1016/S0140-6736(21)01330-1. Erratum in: Lancet. 2022;399(10324):520. DOI:10.1016/S0140-6736(22)00061-7.

2. Egan BM, Kjeldsen SE, Grassi G, et al. The global burden of hypertension exceeds 1.4 billion people: should a systolic blood pressure target below 130 become the universal standard? J Hypertens. 2019;37(6):1148-53. DOI:10.1097/HJH.0000000000002021.

3. de la Sierra A, Ruilope LM, Staplin N, et al. Resistant Hypertension and Mortality: An Observational Cohort Study. Hypertension. 2024;81(11):2350-6. DOI:10.1161/HYPERTENSIONAHA.124.23276.

4. Buhnerkempe MG, Prakash V, Botchway A, et al. Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort. Hypertension. 2021:77(1):72-81. DOI:10.1161/HYPERTENSIONAHA.120.15064.

5. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. DOI:10.1002/14651858.CD000011.pub4.

6. Tajeu GS, Kent ST, Huang L, et al. Antihypertensive Medication Nonpersistence and Low Adherence for Adults <65 Years Initiating Treatment in 2007-2014. Hypertension. 2019;74(1):35-46. DOI:10.1161/HYPERTENSIONAHA.118.12495.

7. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019;124(1):1124-40. DOI:10.1161/CIRCRESAHA.118.313220.

8. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009;120(16):1598-605. DOI:10.1161/CIRCULATIONAHA.108.830299.

9. Bochkareva EV, Butina EK, Kim IV, et al. Adherence to antihypertensive medication in Russia: a scoping review of studies on levels, determinants and intervention strategies published between 2000 and 2017. Arch Public Health. 2019;77:43. DOI:10.1186/s13690-019-0366-9.

10. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114-7. DOI:10.1136/bmj.39553.670231.25.

11. Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: a meta-analysis. Patient Prefer Adherence. 2018;12:721-31. DOI:10.2147/PPA.S161151.

12. Lee H, Yano Y, Cho SMJ, et al. Adherence to Antihypertensive Medication and Incident Cardiovascular Events in Young Adults With Hypertension. Hypertension. 2021;77(4):1341-9. DOI:10.1161/HYPERTENSIONAHA.120.16784.

13. Cutler RL, Fernandez-Llimos F, Frommer M, et al. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982. DOI:10.1136/bmjopen-2017-016982.

14. Parekh N, Ali K, Stevenson JM, et al. Incidence and cost of medication harm in older adults following hospital discharge: a multicentre prospective study in the UK. Br J Clin Pharmacol. 2018;84(8):1789-97. DOI:10.1111/bcp.13613.

15. Berra E, Azizi M, Capron A, et al. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently TreatmentResistant Hypertension. Hypertension. 2016;68(2):297-306. DOI:10.1161/HYPERTENSIONAHA.116.07464.

16. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;(2):D000011. DOI:10.1002/14651858.CD000011.

17. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190-6. DOI:10.1016/j.amjhyper.2006.04.006.

18. Lukina YuV, Kutishenko NP, Martsevich SYu, Drapkina OM. Issues of concern and development of classifications of the main parameters of therapy quality and compliance. Part III: quality of pharmacotherapy. Cardiovascular Therapy and Prevention. 2023;22(6):3603. (In Russ.) DOI:10.15829/17288800-2024-4268.

19. Mukhtar O, Weinman J, Jackson SH. Intentional non-adherence to medications by older adults. Drugs Aging. 2014;31(3):149-57. DOI:10.1007/s40266-014-0153-9.

20. Morisky DE, Green LW, Levine DM. Concurrent and Predictive Validity of a SelfReported Measure of Medication Adherence. Medical Care. 1986;24(1):67-74. DOI:10.1097/00005650-198601000-00007.

21. Nikolayev NA, Skirdenko YuP. Russian generic questionnaire for evaluation of compliance to drug therapy. Klinicheskaya Farmakolоgiya i Terapiya. 2018;27(1):74-8. (in Russ.)

22. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the HillBone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15(3):90-6. DOI:10.1111/j.1751-7117.2000.tb00211.x.

23. El Alili M, Vrijens B, Demonceau J, et al. A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence. Br J Clin Pharmacol. 2016;82(1):268-79. DOI:10.1111/bcp.12942.

24. Sideri K, Cockbain J, Van Biesen W, et al. Digital pills for the remote monitoring of medication intake: a stakeholder analysis and assessment of marketing approval and patent granting policies. J Law Biosci. 2022;9(2):lsac029. DOI:10.1093/jlb/lsac029.

25. Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012;12:270. DOI:10.1186/1472-6963-12-270.

26. Park LG, Howie-Esquivel J, Dracup K. Electronic measurement of medication adherence. West J Nurs Res. 2015;37(1):28-49. DOI:10.1177/0193945914524492.

27. Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tan dem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855- 61. DOI:10.1136/heartjnl-2013-305063.

28. Polukhin NV, Nikolic TR, Ekkert NV, et al. The Analysis of the Context of Digital Access to Healthcare in Russia. Sustainability. 2023;15(3):2271. DOI:10.3390/su15032271.

29. Bourque G, Ilin JV, Ruzicka M, et al. Nonadherence Is Common in Patients With Apparent Resistant Hypertension: A Systematic Review and Meta-analysis. Am J Hypertens. 2023;36(7):394-403. DOI:10.1093/ajh/hpad013.

30. Ruzicka M, Leenen FHH, Ramsay T, et al. Use of Directly Observed Therapy to Assess Treatment Adherence in Patients With Apparent Treatment-Resistant Hypertension. JAMA Intern Med. 2019;179(10):1433-4. DOI:10.1001/jamainternmed.2019.1455.

31. Tian JH, Lu ZX, Bachmann MO, Song FJ. Effectiveness of directly observed treatment of tuberculosis: a systematic review of controlled studies. Int J Tuberc Lung Dis. 2014;18(9):1092-8. DOI:10.5588/ijtld.13.0867.

32. Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54(2):167-79. DOI:10.1097/QAI.0b013e3181d9a330. Erratum in: J Acquir Immune Defic Syndr. 2011;56(1):e37-8.

33. Ducroix C, Choudey M, Cornic F, et al. Directly observed therapy (DOT) in a psychiatric consulting dispensary, long term practice and retrospective study of patients coming every day [abstract]. European Psychiatry. 2007;22(1):S207. DOI:10.1016/j.eurpsy.2007.01.688.

34. Ruzicka M, McCormick B, Leenen FHH, et al. Adherence to blood pressure-lowering drugs and resistant hypertension: should trial of direct observation therapy be part of preassessment for renal denervation? Can J Cardiol. 2013;29(12):1741. e1-3. DOI:10.1016/j.cjca.2013.07.678.

35. Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal Sympathetic Denervation in Patients With Treatment-Resistant Hypertension After Witnessed Intake of Medication Before Qualifying Ambulatory Blood Pressure. Hypertension. 2013;62(3):526-32. DOI:10.1161/HYPERTENSIONAHA.113.01452.

36. Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension 2014;63(5):991-9. DOI:10.1161/HYPERTENSIONAHA.114.03246.

37. Hjørnholm U, Aamodt M, Larstorp AC, et al. Directly Observed Therapy in Hypertension (DOT-HTN). In: Burnier M, editor. Drug Adherence in Hypertension and Cardiovascular Protection, Cham: Springer International Publishing; 2018, p. 57-85. DOI:10.1007/978-3-319-76593-8_6.

38. Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2016;30(2):83-9. DOI:10.1038/jhh.2015.38.

39. Hjørnholm U, Larstorp ACK, Andersen MH, Høieggen A. Directly observed therapy prior to ambulatory blood pressure measurement (DOT-HTN) in uncontrolled hypertensive patients — Effect on blood pressure, safety and patient perception. Blood Press. 2019;28(5):327-35. DOI:10.1080/08037051.2019.1633907.

40. Heimark S, Eskås PA, Mariampillai JE, et al. Tertiary work-up of apparent treatment-resistant hypertension. Blood Press. 2016;25(5):312-8. DOI:10.3109/08037051.2016.1172865.

41. Ionov MV, Emelyanov IV, Vakhrushev AD, et al. Experience of using multielectrode catheter systems to perform radiofrequency renal sympathetic denervation in patients with resistant hypertension: immediate procedural effects. Russian Journal of Cardiology. 2022;27(2):4794. (In Russ.) DOI:10.15829/1560-4071-2022-4794.

42. Pio-Abreu A, Trani-Ferreira F, Silva GV, et al. Directly observed therapy for resistant/refractory hypertension diagnosis and blood pressure control. Heart. 2022;108(24):1952-6. DOI:10.1136/heartjnl-2022-320802.

43. Browne SH, Umlauf A, Tucker AJ, et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. PLoS Med. 2019;16(10):e1002891. DOI:10.1371/journal.pmed.1002891.

44. Ionov MV, Zhukova OV, Yudina YS, et al. Value-based approach to blood pressure telemonitoring and remote counseling in hypertensive patients. Blood Press. 2021;30(1):20-30. DOI:10.1080/08037051.2020.1813015.

45. Versmissen J, van Steenkiste J, Koch BCP, Peeters LEJ. “Under pressure”: The role of therapeutic drug monitoring in the treatment of hypertension. Br J Clin Pharmacol. 2024;90(8):1884-91. DOI:10.1111/bcp.16125.

46. Iriarte G, Gonzalez O, Ferreirós N, et al. Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(27):3045-53. DOI:10.1016/j.jchromb.2009.07.018.

47. Gonzalez O, Iriarte G, Rico E, et al. LC-MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878(28):2685-92. DOI:10.1016/j.jchromb.2010.07.026.

48. Brinker S, Pandey A, Ayers C, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63(8):834-5. DOI:10.1016/j.jacc.2013.10.067.

49. Ceral J, Habrdova V, Vorisek V, et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87-90. DOI:10.1038/hr.2010.183.

50. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766-74. DOI:10.1097/HJH.0b013e32835e2286.

51. Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927-37. DOI:10.1016/S0140-6736(22)02034-7. Erratum in: Lancet. 2023;401(10373):268. DOI:10.1016/S0140-6736(23)00119-8.

52. Strauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455-61. DOI:10.1097/HJH.0b013e3283652c61.

53. Peeters LEJ, Feyz L, Boersma E, et al. Clinical Applicability of Monitoring Antihypertensive Drug Levels in Blood. Hypertension. 2020;76(1):80-6. DOI:10.1161/HYPERTENSIONAHA.120.15038.

54. de Jager RL, Maarseveen EM van, Bots ML, Blankestijn PJ.; SYMPATHY investigators. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018;84(1):18-24. DOI:10.1111/bcp.13402.

55. Bernieh D, Lawson G, Tanna S. Quantitative LC-HRMS determination of selected cardiovascular drugs, in dried blood spots, as an indicator of adherence to medication. J Pharm Biomed Anal. 2017;142:232-43. DOI:10.1016/j.jpba.2017.04.045.

56. Avataneo V, Fanelli E, De Nicolò A, et al. A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. Front Pharmacol. 2022;12:755184. DOI:10.3389/fphar.2021.755184.

57. Sharma JR, Dludla PV, Dwivedi G, Johnson R. Measurement Tools and Utility of Hair Analysis for Screening Adherence to Antihypertensive Medication. Glob Heart. 2023;18(1):17. DOI:10.5334/gh.1191.

58. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487- 97. DOI:10.1056/NEJMra050100.

59. Chung O, Vongpatanasin W, Bonaventura K, et al. Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. J Hypertens. 2014;32(12):2411-21; discussion 2421. DOI:10.1097/HJH.0000000000000346.

60. Nomura A, Tanigawa T, Kario K, Igarashi A. Cost-effectiveness of digital therapeutics for essential hypertension. Hypertens Res. 2022;45(10):1538-48. DOI:10.1038/s41440-022-00952-x.

61. Gupta P, Patel P, Štrauch B, et al. Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension. 2017;70(5):1042-8. DOI:10.1161/HYPERTENSIONAHA.117.09631.

62. Lane D, Patel P, Khunti K, Gupta P. Objective measures of non-adherence in cardiometabolic diseases: a review focused on urine biochemical screening. Patient Prefer Adherence. 2019;13:537-47. DOI:10.2147/PPA.S162215.

63. Lane D, Lawson A, Burns A, et al.; Endorsed by the European Society of Hypertension (ESH) Working Group on Cardiovascular Pharmacotherapy and Adherence. Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension. 2022;79(1):12-23. DOI:10.1161/HYPERTENSIONAHA.121.17596.

64. Kichou B, Henine N, Himeur Y, et al. [Assessment of adherence to antihypertensive drugs in patients with resistant hypertension receiving optimal treatment]. Ann Cardiol Angeiol (Paris). 2019;68(4):264-8. (In French). DOI:10.1016/j.ancard.2019.07.002.

65. Zeijen VJM, Peeters LEJ, Asman A, et al. Quality-of-life and beliefs about medication in relation to a therapy adherence intervention in resistant hypertension: the Resistant HYpertension: MEasure to ReaCh Targets trial. J Hypertens. 2024;42(10):1687-94. DOI:10.1097/HJH.0000000000003780.

66. Punt AM, Stienstra NA, van Kleef MEA, et al. Screening of cardiovascular agents in plasma with LC-MS/MS: A valuable tool for objective drug adherence assessment. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1121:103-10. DOI:10.1016/j.jchromb.2019.05.013.

67. Sheppard JP, Albasri A, Gupta P, et al. Measuring adherence to antihypertensive medication using an objective test in older adults attending primary care: cross-sectional study. J Hum Hypertens. 2022;36(12):1106-12. DOI:10.1038/s41371-021-00646-w.

68. Lawson AJ, Hameed MA, Brown R, et al. Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J Hypertens. 2020;38(6):1165-73. DOI:10.1097/HJH.0000000000002398.

69. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42. DOI:10.1161/CIRCULATIONAHA.111.068064.

70. Patel P, Gupta PK, White CM, et al. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30(6):368-73. DOI:10.1038/jhh.2015.103.

71. Velasco A, Chung O, Raza F, et al. Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension. J Clin Hypertens (Greenwich). 2015;17(9):713-9. DOI:10.1111/jch.12570.

72. Höcht C, Bertera FM, Mayer MA, Taira CA. Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers. Expert Opin Drug Metab Toxicol. 2010;6(2):199-211. DOI:10.1517/17425250903397381.

73. Rodina TA, Melnikov ES, Belkov SA, et al. Therapeutic drug monitoring of nifedipine by HPLC-MS/MS in treatment of arterial hypertension. Biomedicine. 2017;(4):53- 69. (In Russ.)

74. Seleznev SV, Yаkushin SS, Mylnikov PY, et al. Therapeutic Drug Monitoring in Uncontrolled Arterial Hypertension: Result of the Pilot Part of Study. I.P. Pavlov Russian Medical Biological Herald.2023;31(2):195-202 (In Russ.) DOI:10.17816/PAVLOVJ119880.

75. Choudhry NK, Kronish IM, Vongpatanasin W, et al.; American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension. 2022;79(1):e1-14. DOI:10.1161/HYP.0000000000000203.

76. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med. 1990;150(7):1509-10. DOI:10.1001/archinte.1990.00390190143023.

77. Eskås PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016;25(4):199-205. DOI:10.3109/08037051.2015.1121706.

78. Durand H, Hayes P, Harhen B, et al. Medication adherence for resistant hypertension: Assessing theoretical predictors of adherence using direct and indirect adherence measures. Br J Health Psychol. 2018;23(4):949-66. DOI:10.1111/bjhp.12332.

79. Linicus Y, Kindermann I, Helfer AG, et al. Witnessed drug intake before planned denervation--always harmless? Int J Cardiol. 2015;179:125-6. DOI:10.1016/j.ijcard.2014.10.162.

80. Halvorsen LV, Bergland OU, Søraas CL, et al. Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7‐Year Follow‐Up of Patients Considered Adherent by Directly Observed Therapy. J Am Heart Assoc. 2022;11(18):e025879. DOI:10.1161/JAHA.121.025879.

81. Burnier M, Persu A, Azizi M, Prejbisz А. Patient perspectives on treatment adherence in hypertension: preliminary results of an ESH survey in five countries [abstract]. J Hypertens. 2022;40(Suppl 1):e61. DOI:10.1097/01.hjh.0000835756.15202.e5.

82. Lazebnik LB, Podkopaev DV, Komissarenko IA, Mikheeva OM. How to increase compliance in hypertensive patients? Arterial Hypertension 2011;17(3):240- 5. (In Russ.) DOI: 10.18705/1607-419X-2011-17-3-240-245.

83. Burnier M, Prejbisz A, Weber T, et al. Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Press. 2021;30(5):282-90. DOI:10.1080/08037051.2021.1963209.